RE:something could be brewingThat would be very interesting. Thanks digitel for those finds.
In AEZS recent MD&A, it shows they broke off talks with the strategic advisor in October:
In March 2019, the Special Committee approved the engagement of Torreya, a global investment bank specializing in life sciences, as its financial advisor. Torreya was working with management to assist the Special Committee and the board of directors in considering a wide range of transactions, including opportunities for the license of macimorelin outside of the United States and Canada, other monetization transactions relating to macimorelin or the potential sale of the Company, which may create value for our shareholders and other stakeholders. In October 2019, the Company ended its arrangement with Torreya and re-commenced business development activities on its own. Based on the contract with Torreya, should the Company agree to license macimorelin to certain companies in a defined period of time after the cancellation of the contract the Company would owe a fee to Torreya.
Ciao has great points here too on the synergies of pipline and Nasdaq listing.